Ocular touts patient experience data for Dextenza implant

Ocular Therapeutix (NSDQ:OCUL) touted data today from a patient experience study of its Dextenza post-surgical pain relief implant. The study was published in Patient Preference and Adherence. 

The Bedford, Mass.-based company’s hydrogel plug, inserted into a patient’s tear duct, is designed to deliver a sustained dose of dexamethasone over 4 weeks following ophthalmic surgery. After the treatment is complete, the plug resorbs and exits the nasolacrimal system without the need for a removal procedure.

Get the full story at our sister site, Drug Delivery Business News.

The post Ocular touts patient experience data for Dextenza implant appeared first on MassDevice.

from MassDevice http://ift.tt/2nnjJOf